Inside Nephrology: A Weekly Review
Nefrologia
Advances in Urothelial Carcinoma and Renal Cell Carcinoma Treatments
This episode covers groundbreaking studies in urologic oncology including adjuvant nivolumab for urothelial carcinoma, combination immunotherapy for renal cell carcinoma, management of kidney stones, pediatric UTI treatment, and novel therapies for CKD-related anemia.
Bibliography
1. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
2. Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial.
Authors: Montini G, Tessitore A, Console K, et al.
Journal: Pediatrics, 2024 Jan 1
PMID: 38146260
DOI: 10.1542/peds.2023-062598
3. Roxadustat for CKD-related anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis.
Authors: Elkoumi O, Elkoumi A, Elbairy MK, et al.
Journal: BMC nephrology, 2026 May 25
PMID: 42185813
DOI: 10.1186/s12882-025-04723-x
4. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse.
Authors: Sorensen MD, Harper JD, Borofsky MS, et al.
Journal: The New England journal of medicine, 2022 Aug 11
PMID: 35947709
DOI: 10.1056/NEJMoa2204253
5. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
6. IgA Vasculitis with necrotizing arteritis: a multicenter retrospective study from the French Vasculitis Study Group and systematic review of the literature.
Authors: Ribereau-Gayon E, Carbonnelle-Puscian A, Ottavi M, et al.
Journal: Autoimmunity, 2026 Dec 31
PMID: 42192510
DOI: 10.1080/08916934.2026.2677546
7. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Authors: Tannir NM, Albigès L, McDermott DF, et al.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Nov
PMID: 39098455
DOI: 10.1016/j.annonc.2024.07.727
8. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
9. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Authors: Tannir NM, Albigès L, McDermott DF, et al.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Nov
PMID: 39098455
DOI: 10.1016/j.annonc.2024.07.727
10. Artificial Intelligence Across the Drug Development Lifecycle.
Authors: Demyashkin G, Parshenkov M, Zyryanov S, et al.
Journal: Medical sciences (Basel, Switzerland), 2026 May 10
PMID: 42201040
DOI: 10.3390/medsci14020248
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
2. Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial.
Authors: Montini G, Tessitore A, Console K, et al.
Journal: Pediatrics, 2024 Jan 1
PMID: 38146260
DOI: 10.1542/peds.2023-062598
3. Roxadustat for CKD-related anemia in patients undergoing peritoneal dialysis: a systematic review and meta-analysis.
Authors: Elkoumi O, Elkoumi A, Elbairy MK, et al.
Journal: BMC nephrology, 2026 May 25
PMID: 42185813
DOI: 10.1186/s12882-025-04723-x
4. Removal of Small, Asymptomatic Kidney Stones and Incidence of Relapse.
Authors: Sorensen MD, Harper JD, Borofsky MS, et al.
Journal: The New England journal of medicine, 2022 Aug 11
PMID: 35947709
DOI: 10.1056/NEJMoa2204253
5. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
6. IgA Vasculitis with necrotizing arteritis: a multicenter retrospective study from the French Vasculitis Study Group and systematic review of the literature.
Authors: Ribereau-Gayon E, Carbonnelle-Puscian A, Ottavi M, et al.
Journal: Autoimmunity, 2026 Dec 31
PMID: 42192510
DOI: 10.1080/08916934.2026.2677546
7. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Authors: Tannir NM, Albigès L, McDermott DF, et al.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Nov
PMID: 39098455
DOI: 10.1016/j.annonc.2024.07.727
8. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Authors: Bajorin DF, Witjes JA, Gschwend JE, et al.
Journal: The New England journal of medicine, 2021 Jun 3
PMID: 34077643
DOI: 10.1056/NEJMoa2034442
9. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Authors: Tannir NM, Albigès L, McDermott DF, et al.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Nov
PMID: 39098455
DOI: 10.1016/j.annonc.2024.07.727
10. Artificial Intelligence Across the Drug Development Lifecycle.
Authors: Demyashkin G, Parshenkov M, Zyryanov S, et al.
Journal: Medical sciences (Basel, Switzerland), 2026 May 10
PMID: 42201040
DOI: 10.3390/medsci14020248
